Severe myelotoxicity in a combination of gefitinib and vinorelbine [2]

Lung Cancer

Volumn 45, Issue 1, 2004, Pages 121-123

  Yoshimura, Mana ^a   Imamura, Fumio ^a   Ueno, Kiyonobu ^a   Yamamoto, Suguru ^a   Igarashi, Tsuyoshi ^b   Nakamura, Shinichiro ^b  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA POLICE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL;

ANEMIA; BONE MARROW TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; DEATH; DERMATITIS; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEBRILE NEUTROPENIA; HUMAN; INTERSTITIAL LUNG DISEASE; LETTER; LEUKOPENIA; LIVER MICROSOME; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR REGRESSION;

EID: 2942542686     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.01.006     Document Type: Article

References (9)

1. Fukuoka M., Yano S., Giaccone G. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21:2003;2237-2246
2. Giaccone G., Johnson D.H., Manegold C. A phase III trial of ZD 1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy- naïve patients with advanced non-small-cell lung cancer (INTACT 1). Ann. Oncol. 13(Suppl. 5):2002;2-3. [Abstract 4 O]
3. Johnson D.H., Herbst R., Giaccone G. ZD 1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann. Oncol. 13(Suppl. 5):2002;127-128. [Abstract 468 O]
4. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
5. Sugiyama K, Yamashita K., Nishio K. Synergistic combined effect of vinorelbine and ZD 1839 (Iressa) in NSCLC cell lines which overexpress the phosphorylated EGFR and Erb2. Proc. Am. Assoc. Cancer Res. 44:2003;537. [Abstract 2737]
6. Miyazaki M., Tamura K., Kurata T. Synergistic antitumor activity of ZD 1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK), in combination with vinorelbine in human lung cancer xenografts. Proc. Am. Assoc. Cancer Res. 44:2003;740. [Abstract 3720]
7. Nakagawa K., Tamura T. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD 1839) in Japanese patients with solid malignant tumors. Ann. Oncol. 14:2003;922-930
8. Kajita J., Kuwabara T., Kobayashi H. CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab. Dispos. 28(9):2000;1121-1127
9. Inoue A, Saijo Y. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-9.